Theravance Biopharma(Delisted)
TBPH
17.03
0.00
0.00%
Theravance Biopharma(Delisted)
US · TBPH
#3330 by market cap
Listed 2015
17.03
0.00
0.00%
Live - 5344 symbols - heartbeat 259s ago
· 2026-10-07 19:54
- Market cap
- 884.18M
- P/E (TTM)i
- 16.38
- P/Bi
- 3.05
- EPSi
- 2.06
- Div yieldi
- 0.00%
- 52W posi
- 50%
Reader sentiment
Are you bullish or bearish on TBPH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 0.2 percentage points.
Institutional ownership
- Held by institutions
- 93.30% -0.20pp
- Institutions
- 218
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Hedge Fund53.44%
Mutual Fund35.72%
Individual/Insider6.22%
Public Company2.25%
Private Company1.09%
Government Pension Fund0.59%
Family Office/Trust0.12%
Other0.48%
Top holders as of 2026-07-07
Madison Avenue Partners, LP
17.66% · 9.17M sh
Weiss Asset Management, LLC
14.36% · 7.46M sh
BlackRock
8.79% · 4.56M sh
Newtyn Management, LLC
6.61% · 3.43M sh
Irenic Capital Management LP
5.32% · 2.76M sh
Vanguard Capital Management, LLC
3.94% · 2.04M sh
Rick Winningham
3.33% · 1.73M sh
State Street Global Advisors
2.56% · 1.33M sh
Two Sigma Investments, LP
2.36% · 1.23M sh
D. E. Shaw & Co., L.P.
2.28% · 1.19M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 17 buys · 33 sells
| Name | Role | Stake |
|---|---|---|
| Madison Avenue Partners, LP | -- | 17.66% |
| Weiss Asset Management, LLC | -- | 14.36% |
| Rick Winningham | Chairperson & CEO | 3.33% |
| Brett Grimaud | Senior Vice President | 0.68% |
| Aziz Sawaf | Senior Vice President | 0.65% |
| Rhonda Farnum | Chief Business Officer and Senior VP of Commercial & Medical Affairs | 0.41% |
| Aine Miller | VP of Regulatory, Quality, Clinical Safety & Pharmacovigilance and Head of Ireland Office | 0.37% |
| Dean Mitchell | Lead Independent Director | 0.18% |
| Laurie Smaldone Alsup | Independent Director | 0.14% |
| Donal O'Connor | Independent Director | 0.14% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Rhonda Farnum | Chief Business Officer and Senior VP of Commercial & Medical Affairs | Automatic Disposition | -13,314 | $17.03–17.03 |
| 2026-08-19 | Rick Winningham | Chairperson & CEO | Sale to Issuer | -20,034 | $16.95 |
| 2026-08-19 | Brett Grimaud | Senior Vice President | Sale to Issuer | -7,952 | $16.95 |
| 2026-08-19 | Rhonda Farnum | Chief Business Officer and Senior VP of Commercial & Medical Affairs | Sale to Issuer | -5,667 | $16.95 |
| 2026-08-19 | Aziz Sawaf | Senior Vice President | Sale to Issuer | -8,112 | $16.95 |
| 2026-08-19 | Aine Miller | VP of Regulatory, Quality, Clinical Safety & Pharmacovigilance and Head of Ireland Office | Sale to Issuer | -6,258 | $16.95 |
| 2026-07-06 | Madison Avenue Partners, LP | -- | Open Market Disposition | -6,964 | $17.04–17.17 |
| 2026-06-30 | Madison Avenue Partners, LP | -- | Open Market Disposition | -336,697 | $17.00–17.23 |
| 2026-06-18 | Aine Miller | VP of Regulatory, Quality, Clinical Safety & Pharmacovigilance and Head of Ireland Office | Other Acquisition | +18,750 | -- |
| 2026-06-14 | Rhonda Farnum | Chief Business Officer and Senior VP of Commercial & Medical Affairs | Automatic Disposition | -13,314 | $16.38–16.39 |
| 2026-06-11 | Deepika Pakianathan | Independent Director | Other Acquisition | +6,009 | -- |
| 2026-06-11 | Deepika Pakianathan | Independent Director | Other Derivative Acquisition | +13,398 | $16.64 |
| 2026-06-11 | Dean Mitchell | Lead Independent Director | Other Acquisition | +6,009 | -- |
| 2026-06-11 | Dean Mitchell | Lead Independent Director | Other Derivative Acquisition | +13,398 | $16.64 |
| 2026-06-11 | Donal O'Connor | Independent Director | Other Acquisition | +6,009 | -- |
| 2026-06-11 | Donal O'Connor | Independent Director | Other Derivative Acquisition | +13,398 | $16.64 |
| 2026-06-11 | Susannah Gray | Independent Director | Other Acquisition | +6,009 | -- |
| 2026-06-11 | Susannah Gray | Independent Director | Other Derivative Acquisition | +13,398 | $16.64 |
| 2026-06-11 | Laurie Smaldone Alsup | Independent Director | Other Acquisition | +6,009 | -- |
| 2026-06-11 | Laurie Smaldone Alsup | Independent Director | Other Derivative Acquisition | +13,398 | $16.64 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.